Jeff Baxter, VBI’s President and CEO, sat down with Henry Truc, Executive Editor for Equities.com, to discuss VBI, the vaccine landscape, and CMV. The interview was conducted last month at the Small-Cap Stars…
VBI Vaccines, has raised $250,000 in funding, according to federal documents. The latest round raises the total amount of funding VBI has received since inception to more than $14 million….
VBI Vaccines has raised $2.2 million in debt financing, federal documents show.
VBI Vaccines has completed the acquisition of Epixis, a French company developing virus-like particle (VLP) vaccines on its eVLP platform. The acquisition is complementary to VBI’s suite of thermostable vaccine…
VBI Vaccines has completed its acquisition of France’s Epixis for an undisclosed sum, giving the company rights to Epixis’ platform technology for a new generation of virus-like particle (VLP) vaccines.
Cambridge-based vaccine developer Variation Biotechnologies Inc. has raised a combined $7.8 million in a pair of debt financings, according to federal documents filed yesterday.
Expect to hear more about the vaccine developer VBI this year. The company has made some progress in addressing a major bugaboo in the vaccine field—the need to keep the…